BEIJING TIANTAN BIOLOGICAL PRODUCTS CO., LTD. Financials Beijing Tiantan Biological Products Co., Ltd.
Equities
600161
CNE000000WF9
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 28.55 CNY | -0.80% |
|
-0.49% | -7.72% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 29,208 | 52,310 | 39,767 | 39,103 | 50,983 | 47,045 | - | - |
| Enterprise Value (EV) 1 | 29,208 | 52,310 | 39,767 | 39,103 | 50,983 | 47,045 | 47,045 | 47,045 |
| P/E ratio | 48.2 x | 81.8 x | 50.8 x | 44.8 x | 46.2 x | 34.6 x | 28.6 x | 24.1 x |
| Yield | 0.21% | 0.24% | 0.35% | 0.21% | 0.48% | 0.53% | 0.79% | 0.71% |
| Capitalization / Revenue | 8.9 x | 15.2 x | 9.67 x | 9.18 x | 9.84 x | 7.69 x | 6.44 x | 5.57 x |
| EV / Revenue | 8.9 x | 15.2 x | 9.67 x | 9.18 x | 9.84 x | 7.69 x | 6.44 x | 5.57 x |
| EV / EBITDA | 24.7 x | 42 x | 28.6 x | 24.4 x | 24.6 x | 20.7 x | 17 x | 14.2 x |
| EV / FCF | 219 x | 558 x | -278 x | - | - | 43.5 x | 29.6 x | 25.8 x |
| FCF Yield | 0.46% | 0.18% | -0.36% | - | - | 2.3% | 3.38% | 3.87% |
| Price to Book | 7.42 x | 11.6 x | 4.94 x | 4.45 x | 5.19 x | 4.42 x | 3.96 x | 3.53 x |
| Nbr of stocks (in thousands) | 1,505,334 | 1,505,334 | 1,647,816 | 1,647,810 | 1,647,810 | 1,647,810 | - | - |
| Reference price 2 | 19.40 | 34.75 | 24.13 | 23.73 | 30.94 | 28.55 | 28.55 | 28.55 |
| Announcement Date | 4/1/20 | 4/26/21 | 1/10/22 | 1/13/23 | 1/11/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 3,282 | 3,446 | 4,112 | 4,261 | 5,180 | 6,117 | 7,303 | 8,444 |
| EBITDA 1 | 1,182 | 1,247 | 1,392 | 1,603 | 2,074 | 2,277 | 2,769 | 3,317 |
| EBIT 1 | 1,047 | 1,105 | 1,245 | 1,432 | 1,805 | 2,172 | 2,633 | 3,100 |
| Operating Margin | 31.92% | 32.06% | 30.27% | 33.61% | 34.84% | 35.51% | 36.05% | 36.71% |
| Earnings before Tax (EBT) 1 | 1,043 | 1,105 | 1,241 | 1,426 | 1,799 | 2,167 | 2,628 | 3,096 |
| Net income 1 | 611.1 | 639 | 760 | 881 | 1,110 | 1,348 | 1,634 | 1,926 |
| Net margin | 18.62% | 18.55% | 18.48% | 20.68% | 21.42% | 22.04% | 22.38% | 22.81% |
| EPS 2 | 0.4028 | 0.4250 | 0.4750 | 0.5300 | 0.6700 | 0.8250 | 1.000 | 1.184 |
| Free Cash Flow 1 | 133.1 | 93.81 | -142.8 | - | - | 1,082 | 1,589 | 1,820 |
| FCF margin | 4.06% | 2.72% | -3.47% | - | - | 17.69% | 21.76% | 21.55% |
| FCF Conversion (EBITDA) | 11.26% | 7.52% | - | - | - | 47.51% | 57.38% | 54.87% |
| FCF Conversion (Net income) | 21.78% | 14.68% | - | - | - | 80.26% | 97.23% | 94.48% |
| Dividend per Share 2 | 0.0417 | 0.0833 | 0.0833 | 0.0500 | 0.1500 | 0.1500 | 0.2247 | 0.2030 |
| Announcement Date | 4/1/20 | 4/26/21 | 1/10/22 | 1/13/23 | 1/11/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|
| Net sales 1 | 1,222 | 1,623 | 1,562 | 1,382 | 1,659 | 1,866 |
| EBITDA | - | - | - | - | - | - |
| EBIT | - | - | - | - | - | - |
| Operating Margin | - | - | - | - | - | - |
| Earnings before Tax (EBT) | - | - | - | - | - | - |
| Net income | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 4/25/24 | - | - | - | - | - |
1CNY in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | 133 | 93.8 | -143 | - | - | 1,082 | 1,589 | 1,820 |
| ROE (net income / shareholders' equity) | 16.7% | 15.1% | 11.1% | 10.5% | 11.9% | 12% | 13% | 13.5% |
| ROA (Net income/ Total Assets) | 10.7% | 9.22% | 7.98% | 9.31% | - | 9.3% | 9.78% | 10.3% |
| Assets 1 | 5,691 | 6,928 | 9,526 | 9,463 | - | 14,495 | 16,719 | 18,702 |
| Book Value Per Share 2 | 2.620 | 3.000 | 4.890 | 5.340 | 5.960 | 6.460 | 7.220 | 8.080 |
| Cash Flow per Share 2 | 0.4300 | 0.4700 | 0.5900 | 0.6800 | 1.450 | 0.9200 | 1.360 | 1.340 |
| Capex 1 | 509 | 608 | 1,123 | 1,353 | 1,077 | 911 | 1,224 | 1,032 |
| Capex / Sales | 15.52% | 17.65% | 27.31% | 31.76% | 20.79% | 14.9% | 16.75% | 12.22% |
| Announcement Date | 4/1/20 | 4/26/21 | 1/10/22 | 1/13/23 | 1/11/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
28.55
CNY
Average target price
31.86
CNY
Spread / Average Target
+11.58%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -7.72% | 6.49B | |
| -4.67% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -16.09% | 15.36B | |
| -9.14% | 11.95B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| +5.24% | 8.71B |
- Stock Market
- Equities
- 600161 Stock
- Financials Beijing Tiantan Biological Products Co., Ltd.
